Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules

Current Medical Research and Opinion

Volumn 19, Issue 6, 2003, Pages 519-525

  Garnett, William R ^a   McLean, Angus M ^b   Zhang, Yuxin ^c   Clausen, Susan ^c   Tulloch, Simon J ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BioPharm Global Inc   (United States)

^c Shire Pharmaceutical Devmt Inc   (United States)

Author keywords

Adherence; Carbamazepine; Dosing; Models

Indexed keywords

CARBAMAZEPINE; MICROTROL;

ANTICONVULSANT THERAPY; COMPARTMENT MODEL; COMPUTER SIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; EPILEPSY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PATIENT COMPLIANCE; PREDICTION; SLOW RELEASE FORMULATION;

ANTICONVULSANTS; CAPSULES; CARBAMAZEPINE; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; TREATMENT REFUSAL;

EID: 0141793923     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002144     Document Type: Conference Paper

References (18)

1. Karceski S, Morrell M, Carpenter D. The Expert Consensus Guideline Series: Treatment of Epilepsy. Epilepsy Behav 2001;2:A1-50
2. Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type. Neurology 1984;34(9):1252-5
3. Schmidt D, Einicke I, Haenel F. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine. Arch Neurol 1986;43(3):263-5
4. Eichelbaum M, Ekbom K, Bertilsson L, Ringberger VA, Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1975;8(5):337-41
5. Geradin AP, Abadie FV, Campestrini JA, Theobald W. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacokinet Biopharm 1976;4(6):521-35
6. Eichelbaum M, Kothe KW, Hoffman F, von Unruh GE. Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmacol Ther 1979;26(3):366-71
7. Jensen PK, Moller A, Gram L, Jensen NO, Dam M. Pharmacokinetic comparison of two carbamazepine slow-release formulations. Acta Neurol Scand 1990;82(2):135-7
8. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6(5):592-9
9. Macphee GJ, Brodie MJ. Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism. Postgrad Med J 1985;61(719):779-83
10. Hoppener RJ, Kuyer A, Meijer JW, Hulsman J. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980;21(4):341-50
11. Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol 1984;41(8):830-4
12. Riva R, Albani F, Ambrosetto G, Contin M, Cortelli P, Perucca E, et al. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 1984;25(4):476-81
13. Garnett WR, Levy B, McLean AM, Zhang Y, Couch RA, Rudnic EM, et al. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia 1998;39(3):274-9
14. Mirza WU, Rak IW, Thadani VM, Cereghino JJ, Garnett WR, Brown LM, et al. Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology 1998;51(6):1727-9
15. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261(22):3273-7
16. McLean A, Browne S, Zhang Y, Slaughter E, Halstenson C, Couch R. The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation. J Clin Pharmacol 2001;41(2):183-6
17. Garnett WR. Carbamazepine. In Muphy JE, ed. Clinical Pharmacokinetics, 2nd edn. Washington, DC: American Society of Health-Systems Pharmacist, 2001:97-117
18. Kutt H, Penry JK. Usefulness of blood levels of antiepileptic drugs. Arch Neurol 1974;31(5):283-8